Clinical Trials for Sarcoma

A Phase 1 Study of the Safety and Efficacy of CRX100 as Monotherapy and in Combination With Pembrolizumab in Advanced Solid Malignancies

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial targets adult patients with advanced solid malignancies and evaluates the safety and efficacy of CRX100, an investigational immunotherapy combining autologous T cells and oncolytic vaccinia virus, as monotherapy and in combination with Pembrolizumab.

ClinicalTrials.gov ID: NCT04282044

A Phase 1/2, Open-label, Dose-escalation, and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Therapeutic Activity of GI-101 As a Single Agent and in Combination with Pembrolizumab, Lenvatinib or Local Radiotherapy in Patients with Advanced or Metastatic Solid Tumors (Keynote B59)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves adult patients with advanced or metastatic solid tumors and evaluates the safety and therapeutic activity of GI-101, a bispecific fusion protein targeting CTLA-4 and the IL-2 pathway, as a single agent and in combination with pembrolizumab, lenvatinib, or radiotherapy.

ClinicalTrials.gov ID: NCT04977453

A Phase 1a/1b, Open-Label, Multi-Center, Dose Escalation and Expansion Study of HFB200301 (TNFR2 Agonist Antibody) as a Single Agent and in Combination With Tislelizumab (Anti-PD-1 Antibody) in Adult Patients With Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with advanced or metastatic solid tumors (including gastric, renal, melanoma, sarcoma, testicular germ cell, cervical, mesothelioma, NSCLC, or head and neck cancers) who have progressed after standard therapies, and investigates the investigational TNFR2 agonist antibody HFB200301 (stimulating anti-tumor immunity) as monotherapy or in combination with the anti-PD-1 antibody tislelizumab. Eligible patients must have measurable disease, ECOG 0-1, and no prior TNFR2-targeted therapy or active autoimmune disease.

ClinicalTrials.gov ID: NCT05238883

A Phase IIIb, Randomized, Multicenter, Open-label Study to Assess the Efficacy of Durvalumab Plus Tremelimumab Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for First-line Treatment in Metastatic Non-small Cell Lung Cancer Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls adults with previously untreated metastatic non-squamous NSCLC harboring STK11, KEAP1, or KRAS mutations (excluding EGFR/ALK), and randomizes them to durvalumab (PD-L1 inhibitor) plus tremelimumab (CTLA-4 antibody) with platinum-pemetrexed chemotherapy versus pembrolizumab (PD-1 inhibitor) with the same chemotherapy. Eligible patients must have ECOG 0-1 and measurable disease.

ClinicalTrials.gov ID: NCT06008093

Phase II Trial of Lung Chemoemobolization

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with unresectable, unablatable non-small cell lung cancer or lung metastases progressing on or intolerant to systemic therapy receive transarterial chemoembolization (TACE) with intra-arterial mitomycin (alkylating cytotoxic agent), lipiodol (contrast/drug carrier), and embospheres (arterial embolic microspheres). This trial targets patients not eligible for surgery, ablation, or radiation, assessing local disease control using a locoregional approach.

ClinicalTrials.gov ID: NCT05672108

A Pilot Study of Spatially Fractionated Radiation Therapy in Patients with Extra-Cranial Soft Tissue Metastases

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls adults with advanced or metastatic solid tumors and at least two extracranial soft tissue metastases (one ≥4 cm) requiring palliative radiation, comparing lattice radiation therapy (LRT)—a spatially fractionated radiotherapy technique that may enhance immune effects—to standard SBRT, with each patient receiving both treatments at different sites.

ClinicalTrials.gov ID: NCT05837767

A Phase 1, Open Label, Dose-Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics and Initial Therapeutic Activity of AVA6000, a Novel FAP-activated Doxorubicin Prodrug Administered Intravenously in Patients With Locally Advanced or Metastatic Selected Solid Tumours

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Eligible patients are adults with locally advanced or metastatic FAP-positive solid tumors, including high-grade soft-tissue sarcoma, salivary gland carcinoma, and triple-negative breast cancer, who have progressed on or are ineligible for standard therapies. Patients receive intravenous AVA6000, a FAP-activated doxorubicin prodrug designed to deliver doxorubicin selectively to tumor tissue in order to minimize systemic toxicity.

ClinicalTrials.gov ID: NCT04969835

A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 in Patients With Advanced Solid Tumors With Homozygous MTAP Deletion

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with unresectable or metastatic solid tumors harboring homozygous MTAP deletion (biopsy-amenable, ECOG 0-1) are eligible to receive MRTX1719, a selective PRMT5 inhibitor targeting the PRMT5-MTA complex, as monotherapy or in combination with standard therapies in expansion cohorts. Prior PRMT5 or MAT2A inhibitor therapy is excluded.

ClinicalTrials.gov ID: NCT05245500

Locally AblatiVe TherApy in OLigO-pRogressive SOlid TUmorS (VALOROUS)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls adults with various solid tumors (including breast, gynecologic, head and neck cancers, and sarcomas) who have oligo-progressive disease (≤5 progressing metastatic lesions) despite ongoing benefit from systemic therapy; patients continue their current systemic treatment and receive locally ablative therapy (via stereotactic ablative radiotherapy or image-guided ablation) to all progressing sites.

ClinicalTrials.gov ID: NCT06103669

A Phase II Study Evaluating Definitive Radiosurgical Decompression in Patients With High-Risk Spinal Metastases

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls adults with solid tumors (excluding CNS primaries and radiosensitive histologies) who have up to three contiguous vertebral levels of spinal metastases and minimal neurological deficit, treating them with spine-directed stereotactic body radiation therapy (SBRT) as definitive therapy instead of surgery. Prior intervention to the target site, unstable spines, and radiosensitive tumors are excluded.

ClinicalTrials.gov ID: NCT06165419